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ABSTRACT 36 
Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of morbidity and 37 
death and imposes major socioeconomic burdens globally. It is a progressive and disabling 38 
condition that severely impairs breathing and lung function. There is a lack of effective 39 
treatments for COPD, which is a direct consequence of the poor understanding of the 40 
underlying mechanisms involved in driving the pathogenesis of the disease. Toll-like receptor 41 
(TLR)2 and TLR4 are implicated in chronic respiratory diseases, including COPD, asthma 42 
and pulmonary fibrosis. However, their roles in the pathogenesis of COPD are controversial 43 
and conflicting evidence exists. In the current study, we investigated the role of TLR2 and 44 
TLR4 using a model of cigarette smoke (CS)-induced experimental COPD that recapitulates 45 
the hallmark features of human disease. TLR2, TLR4 and associated co-receptor mRNA 46 
expression were increased in the airways in both experimental and human COPD. CS-47 
induced pulmonary inflammation was similar in TLR2-deficient (Tlr2-/-), TLR4-deficient 48 
(Tlr4-/-) and WT mice. CS-induced airway fibrosis, characterized by increased collagen 49 
deposition around small airways, was not altered in Tlr2-/- mice but was attenuated in Tlr4-/- 50 
mice compared to CS-exposed WT controls. However, Tlr2-/- mice had increased CS-induced 51 
emphysema-like alveolar enlargement, apoptosis and impaired lung function, whilst these 52 
features were reduced in Tlr4-/- mice compared to CS-exposed WT controls. Taken together, 53 
these data highlight the complex roles of TLRs in the pathogenesis of COPD and suggest that 54 
activation of TLR2 and/or inhibition of TLR4 may be novel therapeutic strategies for the 55 
treatment of COPD. 56 
 57 
Key words: TLR2, TLR4, cigarette smoke, emphysema, COPD 58 
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INTRODUCTION 60 
Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of morbidity and 61 
death and imposes significant socioeconomic burden worldwide (63). It is a complex, 62 
heterogeneous disease characterized by chronic pulmonary inflammation, emphysema and 63 
airway remodeling, which are associated with progressive lung function decline (39). Indeed, 64 
the major disease features are progressive and become more severe over time that is 65 
accelerated by infection-induced exacerbations. Cigarette smoke (CS) is a major risk factor 66 
for COPD (54). The current mainstay therapies for COPD are glucocorticoids, β2-adrenergic 67 
receptor agonists and long acting muscarinic antagonists (5, 93). However, these agents are 68 
largely ineffective and only provide symptomatic relief rather than modifying the causal 69 
factors or stopping disease progression (5). There is much current interest in increased 70 
microbial carriage and altered lung and gut microbiomes in COPD that could be modified for 71 
therapeutic gain and macrolide antibiotics are currently being tested as new treatments (14, 72 
89, 92). Nevertheless, there is currently a lack of effective treatments for COPD that is 73 
largely due to the poor understanding of the underlying mechanisms.  74 
Toll-like receptor (TLR)2 and TLR4 play vital roles in detecting and initiating 75 
immune responses to microbial membrane components (1, 36, 52). TLR2 and TLR4 are type 76 
I transmembrane receptors expressed on the cell surface (1, 36, 52). However, in some 77 
circumstances TLR4 can be internalized or expressed intracellularly in certain cells (1, 36, 78 
52). TLR2 and TLR4 primarily signal through the adaptor protein myeloid differentiation 79 
primary response gene 88 (MyD88)-dependent or MyD88-adapter-like (Mal)-dependent 80 
pathways (1, 36, 52). Upon ligand (e.g. bacterial peptidoglycan) binding TLR2 forms a 81 
heterodimer with either TLR1 or TLR6 and interacts with cluster of differentiation (CD)14 to 82 
form a functional complex (24, 48). In contrast, TLR4 forms a homodimer upon binding to its 83 
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ligand (e.g. bacterial lipopolysaccharide) and interacts with CD14 and/or MD2 (also known 84 
as lymphocyte antigen 96 [LY96] in humans) (57, 108). This initiates the recruitment of 85 
MyD88 to the intracellular Toll–interleukin 1 (IL-1) receptor (TIR) domain, that 86 
subsequently activates members of the IL-1 receptor-associated kinases (IRAKs) and tumor 87 
necrosis factor (TNF) receptor-associated factor 6 (TRAF6) (1, 52). Consequently, 88 
transcriptional factors of the mitogen-activated protein kinase (MAPK) family and nuclear 89 
factor kappa-light-chain-enhancer of activated B cells (NF-κB) are activated, leading to the 90 
expression of pro-inflammatory mediators (1, 36, 52). 91 
TLR2 and TLR4 are widely implicated in chronic respiratory diseases, including 92 
asthma and pulmonary fibrosis (18, 25, 37, 42, 55, 56, 58, 59, 82, 86, 90, 106). Both are 93 
associated with increased susceptibility to asthma and allergies in children (25, 55). In adults, 94 
increased expression of TLR2, TLR4 and CD14 were observed in subjects with 95 
bronchiectasis and asthma (90). These observations were supported by findings from mouse 96 
models of allergic airway disease (18, 37, 59, 82, 106) and bleomycin-induced pulmonary 97 
fibrosis (42, 56, 58, 60, 86). We have also shown that TLR2 was essential in protecting 98 
against early-life respiratory infection and the development of subsequent chronic lung 99 
disease in later life (6, 27, 44, 96, 97). However, the role of TLR2 and TLR4 in the 100 
pathogenesis of COPD remains controversial and conflicting evidence exists in the literature. 101 
Some studies show that TLR2 and TLR4 expression are increased by CS exposure or in 102 
COPD patients (3, 21, 30, 33, 66, 69, 75, 80, 85, 91). However, others show that these TLRs 103 
are either not altered or are decreased by CS exposure or in COPD patients (22, 65, 80, 87).  104 
Hence, the role of TLR2 and TLR4 in the pathogenesis of COPD remains unclear. 105 
Here, we investigated these roles using an established mouse model of CS-induced 106 
experimental COPD that recapitulates the critical features of human disease (7, 29, 31, 40, 107 
41, 47, 62, 100) as well as gene expression analysis of lung tissues from human COPD 108 
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patients. TLR2, TLR4 and associated co-receptor mRNA were increased in the airways in 109 
both experimental and human COPD. Compared to WT controls CS-induced pulmonary 110 
inflammation was largely unaltered in TLR2-deficient (Tlr2-/-) and TLR4-deficient (Tlr4-/-) 111 
mice when compared to WT controls. However, Tlr2-/- mice had increased CS-induced 112 
emphysema-like alveolar enlargement, apoptosis and impaired lung function whilst CS-113 
induced airway fibrosis was not altered compared to WT controls. In contrast, these features 114 
were reduced or completely ablated in Tlr4-/- mice compared to WT controls, thus implicating 115 
this TLR in the pathogenesis of COPD. 116 
 117 
MATERIALS AND METHODS 118 
Ethics statement. This study was performed in accordance with the recommendations issued 119 
by the National Health and Medical Research Council of Australia. All experimental 120 
protocols were approved by the animal ethics committee of The University of Newcastle, 121 
Australia. 122 
 123 
Experimental COPD. Female, 7-8-week-old, wild-type (WT), Tlr2-/- or Tlr4-/- BALB/c mice 124 
were purchased from the Australian Bioresource Facility, Moss Vale, NSW, Australia. Tlr2-/- 125 
and Tlr4-/- mice were generous gifts from Prof. Shizuo Akira, Osaka University, Japan and 126 
generated by using targeting vectors that introduce a targeted mutation in the mouse Tlr2 and 127 
Tlr4 genes as previously described (46, 99). Mice were housed under a 12-hour light/dark 128 
cycle and had free access to food (standard chow) and water. After period of acclimatization 129 
(up to 5 days), mice were randomly placed into experimental groups and exposed to either 130 
normal air or nose-only inhalation of CS for up to twelve weeks as described previously (7, 131 
29, 31, 40, 41, 47, 62, 100). Recently, studies have shown that COPD prevalence and 132 
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mortality are higher in females, and in the United States in 2009 women accounted for 133 
53% of COPD deaths (78). It is for these and logistical reasons that female mice are used. 134 
 135 
Isolation of RNA and qPCR. Total RNA was extracted and reversed transcribed from whole 136 
lung tissue, blunt-dissected airway and parenchyma and isolated lung macrophages (7, 41, 70, 137 
101). mRNA transcripts were determined by real-time quantitative PCR (qPCR, 138 
ABIPrism7000, Applied Biosystems, Scoresby, Victoria, Australia) using custom designed 139 
primers (Integrated DNA Technologies, Baulkham Hills, New South Wales, Australia), 140 
normalized to the reference gene hypoxanthine-guanine phosphoribosyltransferase (HPRT) 141 
and expressed as relative abundance to WT air controls (Table 1) (7, 41, 70, 101). 142 
 143 
Immunohistochemistry. Lungs were perfused, inflated, formalin-fixed, paraffin-embedded 144 
and sectioned (4-6μm). Longitudinal sections of the left lung were rehydrated through a 145 
series of xylene (2x) and ethanol gradient (2x absolute, 90%, 80%, 70%, 50%, 0.85% saline 146 
and phosphate-buffered saline [PBS]) washes followed by antigen retrieval with citrate buffer 147 
(10mM citric acid, 0.05% Tween 20, pH 6.0) at 100°C for 30 mins. Sections were blocked 148 
with casein blocker (Thermo Fisher Scientific, Pittsburgh, PA, USA) for 1 hour. Sections 149 
were then washed with PBS (5x, 5 mins each) and incubated with either anti-TLR2 (1:200 150 
dilution, MABF84, clone 19B6.2, Merck Milipore, Bayswater, Victoria, Australia), anti-151 
TLR4 (1:1000 dilution, ab47093, Abcam, Melbourne, Victoria, Australia) or anti-active 152 
caspase-3 (1:200 dilution, ab13847, Abcam) antibodies followed by either anti-rabbit 153 
(HAF008; R&D Systems, Gymea, New South Wales, Australia) or anti-mouse (ab6728; 154 
Abcam) secondary antibody conjugated with  horseradish peroxidase and then 3,3'-155 
Diaminobenzidine chromogen-substrate buffer (DAKO, North Sydney, New South Wales, 156 
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Australia) according to manufacturer’s instructions (40, 41). Sections were counterstained 157 
with hematoxylin, mounted and analyzed using a BX51 microscope (Olympus, Tokyo, 158 
Shinjuku, Japan) with Image-Pro Plus software (Media Cybernetics, Rockville, MD). The 159 
aAreas of active caspase-3 in lung parenchyma were determined (n=4 per group, 10 160 
randomized parenchyma images per lung sections) using ImageJ software (Version 1.50, 161 
NIH, New York City, NY, USA), normalized to area of hematoxylin and represented as the 162 
percentage area of active caspase-3. Images with inflammation and airways were excluded 163 
from analysis. 164 
 165 
Isolation of lung macrophages. Lungs were excised, washed and dissected into 1-2mm 166 
cubes in Dulbecco’s Modified Eagle Medium (DMEM, Sigma Aldrich, Castle Hill, New 167 
South Wales, Australia). Lung tissues were then transferred into Medicon cassettes (BD 168 
Biosciences, North Ryde, New South Wales, Australia) and disaggregated using a 169 
Medimachine (BD Biosciences) for 2 mins. Cell suspensions were collected, Histopaque 170 
1083 (Sigma Aldrich) applied and centrifuged (825xg, 30 mins, 22.5 °C). The opaque 171 
interface cell layer where macrophages/monocytes were enriched was collected, washed with 172 
Hyclone™ Dulbecco’s PBS (GE Healthcare Life Sciences, South Logan, Utah, USA) and 173 
centrifuged (100xg, 5 mins, 22.5 °C). Cell pellets were resuspended in fresh DMEM (Sigma) 174 
and macrophages further enriched through adherence to plastic tissue culture flasks (3 hrs, 37 175 
°C). Non-adherent contaminating cells were removed by gentle washing with PBS (GE 176 
Healthcare Life Sciences) prior to RNA isolation.  177 
 178 
Flow Cytometry Analysis. The numbers of CD11b+ monocytes, neutrophils and myeloid 179 
dendritic cells (mDCs) in lung homogenates were determined based on surface marker 180 
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expression using flow cytometry (Table 2) (45, 53, 94, 97, 101). Flow cytometric analysis 181 
was performed using a FACSAriaIII with FACSDiva software (BD Biosciences, North Ryde, 182 
Australia). Flow cytometry antibodies were purchased from Biolegend (Karrinyup, Western 183 
Australia, Australia) or BD Biosciences (Table 3). OneComp compensation beads (Thermo 184 
Fisher Scientific) were used to compensate for spectral overlap. 185 
 186 
Gene Expression in Human COPD Microarray Datasets. Analysis of TLR2, TLR4 and 187 
co-receptors gene expression in published human array datasets (Affymetrix Human Genome 188 
U133 Plus 2.0 Array, Accession numbers: GSE5058 and GSE27597) (13, 16, 102) were 189 
performed using the Array Studio software (Omicsoft Corporation, Research Triangle Park, 190 
NC, USA) by applying a general linear model adjusting for age and gender and the 191 
Benjamini–Hochberg method for p-value adjustment (41). Data are expressed as log2 192 
intensity robust multi-array average signals. The Benjamini–Hochberg method for adjusted P 193 
value/false discovery rate (FDR) was used to analyze differences between two groups. 194 
Statistical significance was set at FDR < 0.05. 195 
 196 
Pulmonary Inflammation. Airway inflammation was assessed by differential enumeration 197 
of inflammatory cells in bronchoalveolar lavage fluid (BALF) (7, 27, 40, 41, 62, 70). Lung 198 
sections were stained with periodic acid-Schiff (PAS) and tissue inflammation assessed by 199 
enumeration of inflammatory cells (7, 41, 70). Histopathological score was determined in 200 
lung sections stained with hematoxylin and eosin (H&E) based on established custom-201 
designed criteria (40, 44, 70).  202 
 203 
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Enzyme-linked immunosorbent assay (ELISA). Right lung lobes were homogenized on ice 204 
in 500uL of PBS supplemented with Complete mini protease inhibitor cocktail (Roche 205 
Diagnostic, Sydney, NSW, Australia) and PhosphoSTOP tablets (Roche Diagnostic). Lung 206 
homogenates were incubated on ice for 5 mins and subsequently centrifuged (8,000xg, 15 207 
mins). Supernatants were collected, stored at -20°C overnight and total protein levels were 208 
determined using Pierce BCA assay kit (Thermo Fisher Scientific) prior to enzyme-linked 209 
immunosorbent assays (ELISAs). TNFα protein levels were quantified with mouse TNFα 210 
Duoset ELISA kit as per manufacturer’s instructions (R&D systems). TNFα protein levels 211 
were normalized to total protein in lung homogenates. Hyaluronan protein levels in BALF 212 
were quantified with mouse hyaluronan Quantikine ELISA kits as per manufacturer’s 213 
instructions (R&D systems).  214 
 215 
Airway Remodeling. Lung sections were stained with PAS or Masson’s Trichrome. Airway 216 
epithelial area (μm2), cell (nuclei) number and collagen deposition area (μm2) were assessed 217 
in a minimum of four small airways (basement membrane [BM] perimeter <1,000μm) per 218 
section (7, 40, 41, 62, 70). Data were quantified using ImageJ software (Version 1.50, NIH) 219 
and normalized to BM perimeter (μm). 220 
 221 
Alveolar Enlargement. Lung sections were stained with H&E. Alveolar septal damage and 222 
diameter were assessed by using the destructive index technique (26) and mean linear 223 
intercept technique respectively (7, 41, 47, 62). 224 
 225 
Apoptosis. Lung sections were stained with terminal deoxynucleotidyl transferase dUTP nick 226 
end labeling (TUNEL) assay kits (Promega, Sydney, New South Wales, Australia) according 227 
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to manufacturer’s instructions (41). Apoptosis in lung parenchyma was assessed by 228 
enumerating the numbers of TUNEL+ cells per high power fields (HPF; 100x) (41). 229 
Lung Function. Mice were anaesthetized with ketamine (100mg/kg) and xylazine (10mg/kg, 230 
Troy Laboratories, Smithfield, Australia) prior to tracheostomy. Tracheas were then 231 
cannulated and attached to Buxco® Forced Maneuvers systems apparatus (DSI, St. Paul, 232 
Minnesota, USA) to assess total lung capacity (TLC) (7, 40). Mice were then attached to a 233 
FlexiVent apparatus (FX1 System; SCIREQ, Montreal, Canada) to assess transpulmonary 234 
resistance (tidal volume of 8mL/kg at a respiratory rate of 450 breaths/mins) (7). All 235 
assessments were performed at least three times and the average was calculated for each 236 
mouse. 237 
 238 
Statistical analyses. Data are presented as means ± standard error of mean (SEM) and 239 
representative from two independent experiments with 6 mice per group. The two-tailed 240 
Mann-Whitney test was used to compare two groups. The one-way analysis of variance with 241 
Bonferroni post-test was used to compare 3 or more groups. Statistical significance was set at 242 
P < 0.05 and determined using GraphPad Prism Software version 6 (San Diego, CA, USA).  243 
 244 
RESULTS  245 
TLR2 and TLR4 mRNA Expression and Protein Levels are Increased in 246 
CS-induced Experimental COPD 247 
To determine whether TLR2 and TLR4 levels are altered in COPD, we first interrogated our 248 
mouse model of experimental COPD (7, 29, 31, 40, 41, 47, 62, 100). WT mice were exposed 249 
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to CS for 4, 8 and 12 weeks and TLR2 and TLR4 mRNA expression were assessed. TLR2, 250 
but not TLR4 mRNA was significantly increased in whole lung homogenates after 4, 8 and 251 
12 weeks of CS exposure compared to normal air-exposed mice (Figure 1A-B). We have 252 
previously shown that many of the hallmark features of COPD were established in mice after 253 
8 weeks of CS exposure (7, 29, 31, 40, 41, 47, 62, 100). To determine the compartment of the 254 
lung in which altered TLR2 and TLR4 expression occurred following establishment of 255 
disease, blunt dissected airways and lung parenchyma were assessed at this time point. To 256 
confirm separation of bluntly- dissected airways from parenchymal tissue we assessed the 257 
mRNA expression of airway epithelial cell-specific mucin 5ac (Muc5ac) and the mouse type 258 
II alveolar epithelial cell-marker surfactant protein C (Sftpc) in normal air-exposed mice 259 
(Figure 1C). TAccordingly, the levels of Muc5ac mRNA wereas increased in airways 260 
compared to lung parenchyma (Figure 1C). Conversely, the levels of Sftpc mRNA wereas 261 
increased in lung parenchyma compared to airways (Figure 1C). This confirms the tissue 262 
specific isolation and location of TLR2, TLR4 and co-receptors in these tissues. TLR2 263 
mRNA was increased in both the airways and parenchyma of CS-exposed mice (Figure 1D-264 
E). In contrast, TLR4 mRNA was increased in the airways, but not parenchyma (Figure 1F-265 
G). These mRNA expression data were supported by increased TLR2 (Figure 1H-I) and 266 
TLR4 (Figure 1J-K) protein levels in small airway epithelial cells and increased infiltration of 267 
parenchyma-associated inflammatory cells that expressed TLR2 or TLR4 in lung histology 268 
sections detected by immunohistochemistry. 269 
 To identify the inflammatory cell source of TLR2 and TLR4, macrophages were 270 
isolated from whole lung homogenates for downstream mRNA analysis. Interestingly, the 271 
mRNA expression of TLR2 and TLR4 were not altered in lung macrophages isolated from 272 
CS-exposed mice (Figure 2A-B). CD11b+ monocytes, neutrophils and mDCs are known to 273 
express TLR2 and/or TLR4 (6, 10, 80, 81), and have roles in COPD pathogenesis (41, 91). 274 
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Thus, we next determined whether CS altered the numbers of these immune cells that 275 
expressed TLR2 and/or TLR4 in the lung usingby flow cytometry. CS-exposed mice had 276 
increased the numbers of CD11b+ monocytes that expressed TLR2 (TLR2+), but not those 277 
that expressed TLR4 (TLR4+) or co-expressed TLR2 and TLR4 (TLR2+TLR4+) (Figure 2C) 278 
compared to normal air-exposed controls. In contrast, CS-exposed mice had significantly 279 
increased the numbers of neutrophils and mDCs that were either TLR2+, TLR4+ or 280 
TLR2+TLR4+ (Figure 2D-E) compared to normal air-exposed controls. 281 
 282 
TLR2 and TLR4 Co-receptor mRNA Expression are Increased in CS-283 
induced Experimental COPD 284 
When activated, TLR2 and TLR4 interact with co-receptors TLR1, TLR6, CD14 and/or 285 
MD2/Ly96 to mediate inflammatory responses (1, 36, 52). Therefore, we next determined 286 
whether the mRNA expression of these co-receptors was altered by CS exposure. TLR1 287 
mRNA was increased in blunt dissected lung parenchyma, but not airways compared to 288 
normal air-exposed controls (Figure 3A-B). In contrast, TLR6 and CD14 mRNA were 289 
increased in both airways and parenchyma (Figure 3C-F). MD2/Ly96 mRNA expression was 290 
not altered by CS exposure (Figure 3G-H). 291 
 292 
TLR2, TLR4 and Co-receptor mRNA Expression are Increased in the 293 
Airways in Human COPD 294 
We next sought to determine whether the mRNA expression of TLR2, TLR4 and their co-295 
receptors were altered in humans with mild-to-moderate COPD (Global Initiative for Chronic 296 
Obstructive Lung Disease [GOLD] Stage I or II (103)). Pre-existing microarray data from 297 
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non-COPD (healthy non-smokers and healthy smokers) and COPD patients were interrogated 298 
(13, 16, 102). TLR2, TLR4 and co-receptor (TLR1, TLR6, CD14 and LY96) mRNA 299 
expression were not significantly altered in airway epithelial brushings from healthy smokers 300 
compared to non-smokers (Accession: GSE5058 (102), Figure 4A-F). Importantly, however, 301 
TLR2 (~2.4-fold), TLR4 (~8.7-fold), TLR1 (~7.1-fold), TLR6 (~1.5-fold), CD14 (~3.9-fold) 302 
and LY96 (~12.9-fold) mRNA expression were increased in airway epithelial brushings from 303 
patients with mild-to-moderate COPD compared to non-smokers. Notably, TLR2 (~2.4-fold), 304 
TLR4 (~7.2-fold), TLR1 (~4.7-fold), CD14 (~3.6-fold) and LY96 (~6.8-fold) but not TLR6 305 
(~0.8-fold) mRNA expression were also increased in airway brushings from COPD patients 306 
compared to healthy smokers (Figure 4A-F).  307 
 308 
TLR2, TLR4 and Co-receptor mRNA Expression are Decreased in the 309 
Parenchyma in Human COPD 310 
Similarly, we then assess the expression of TLR2, TLR4 and co-receptor expression in pre-311 
existing microarray data from lung parenchyma cores from severe COPD patients (GOLD 312 
Stage IV (103)) compared to non-smokers without COPD (Accession: GSE27597) (13, 16). 313 
In contrast to the data from the airways, TLR2 (~1.5-fold) and TLR4 (~2.0-fold) expression 314 
were reduced, whereas co-receptors TLR1, TLR6 and LY96 were not altered, in the 315 
parenchyma from severe COPD patients compared to non-smokers without COPD (Figure 316 
4G-K). CD14 was not detectable in this dataset.  317 
 318 
CS-induced Pulmonary Inflammation was Largely Unaltered in TLR2-319 
deficeint and TLR4-deficient mice with Experimental COPD 320 
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We next investigated whether TLR2 and TLR4 play a role in the pathophysiology of CS-321 
induced experimental COPD. WT, Tlr2-/- and Tlr4-/- mice were exposed to normal air or CS 322 
for 8 weeks (7, 29, 31, 40, 41, 47, 62, 100). We first assessed pulmonary inflammation in 323 
BALF by staining and differential enumeration of inflammatory cells. As expected, CS-324 
exposure of WT mice resulted in significantly increased total leukocytes, macrophages, 325 
neutrophils and lymphocytes in BALF compared to normal air-exposed WT controls (Figure 326 
5A-D). CS-exposed Tlr2-/- mice had increased neutrophils and lymphocytes, but not total 327 
leukocytes and macrophages, compared to normal air-exposed Tlr2-/- controls. This was due 328 
to an increase in total leukocytes and macrophages in normal air-exposed Tlr2-/- controls 329 
compared to normal air-exposed WT controls. In contrast, CS-exposed Tlr4-/- mice had 330 
increased total leukocytes, macrophages, neutrophils and lymphocytes in BALF compared to 331 
normal air-exposed Tlr4-/- controls. Importantly, total leukocytes, macrophages, neutrophils 332 
and lymphocytes in BALF were not significantly altered in CS-exposed Tlr2-/- or Tlr4-/- mice 333 
compared to CS-exposed WT controls. 334 
We then assessed inflammatory cell numbers in the parenchymal histology. CS 335 
exposure of WT mice significantly increased inflammatory cell numbers in the parenchyma 336 
compared to normal air-exposed WT controls (Figure 5E). CS-exposed Tlr2-/- and Tlr4-/- mice 337 
also had increased parenchymal inflammatory cells compared to their respective normal air-338 
exposed controls and were not significantly different from CS-exposed WT controls.  339 
Next, histopathology was scored according to a set of custom-designed criteria as 340 
described previously (40, 44). CS exposure of WT mice increased histopathology score 341 
(Figure 5F), which was characterized by increased airway, vascular and parenchymal 342 
inflammation (Figure 5G-I). CS-exposed Tlr2-/- and Tlr4-/- mice also had increased 343 
histopathology, airway, vascular and parenchymal inflammation scores compared to their 344 
respective normal air-exposed controls. Representative images are shown in Figure 5J. Tlr2-/-, 345 
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but not Tlr4-/- mice had a small but significantly increased total histopathology score 346 
compared to CS-exposed WT controls, which was characterized by increased parenchymal 347 
inflammation score. Normal air-exposed Tlr2-/-, but not Tlr4-/- mice also had a small increase 348 
in vascular and parenchymal inflammation scores compared to normal air-exposed WT mice.  349 
We then profiled the mRNA expression of the pro-inflammatory cytokine  tumor 350 
necrosis factor (TNF)-α, chemokine (C-X-C motif) ligand (CXCL)1, chemokine (C-C motif) 351 
ligands (CCL)2, CCL3, CCL4, CCL12, CCL22 and COPD-related factors matrix 352 
metalloproteinase (MMP)-12 and serum amyloid A3 (SAA3, ), (Figure 6A-I). CS exposure 353 
induced thisese cytokines, and these chemokines and factors in WT, Tlr2-/- and Tlr4-/- mice. 354 
However, some were not altered in CS-exposed Tlr2-/- and/or Tlr4-/- mice compared to CS-355 
exposed WT controls, whilst others that showed differences (e.g. increased TNF-α, CXCL1, 356 
CCL2, CCL12 and CCL22 in CS-exposed Tlr4-/- mice compared to CS-exposed WT controls) 357 
in expression but were not consistent with the inflammatory cell profile (Figure 5) observed 358 
in CS-exposed Tlr2-/- and Tlr4-/- mice compared to CS-exposed WT controls. Notably, 359 
however, the mRNA expression of the pro-fibroticsis and emphysema factor MMP-12 360 
(Figure 6H) was significantly reduced in CS-exposed Tlr4-/- mice compared to CS-exposed 361 
WT controls.  362 
Given that TLR2 and TLR4 have been previously shown to play roles in mediating 363 
pulmonary oxidative stress (32, 61, 83, 109), we also profiled the mRNA expression of 364 
NADPH oxidase (Nox)1, Nox2, Nox3, Nox4, NAD(P)H quinone dehydrogenase (Nqo)1, 365 
nuclear factor (erythroid-derived 2)-like-2 factor (Nrf2), glutamate-cysteine ligase catalytic 366 
subunit (Gclc), glutathione peroxidase (Gpx)2, heme oxygenase (Hmox)1 and glutathione S-367 
transferase pi (Gstp)1 (Figure 6J-S). CS exposure induced the expression of Nox2 (Figure 368 
6K) and suppressed Gstp1 (Figure 6S), whilst other genes were not altered, in Tlr2-/- or Tlr4-/- 369 
mice compared to WT controls. Interestingly, Nox3 (Figure 6L) was increased in normal air-370 
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exposed Tlr4-/- mice compared to normal air-exposed WT controls, but was reduced by CS 371 
exposure. Other oxidative stress-associated genes were, however, not significantly altered in 372 
normal air-exposed Tlr2-/- or Tlr4-/- mice compared to normal air-exposed WT controls.  373 
 To determine whether the TNFα signaling pathway was altered in CS-exposed Tlr4-/- 374 
mice, we next assessed the levels of TNFα protein in lung homogenates. As expected, TNFα 375 
protein levels were increased in CS-exposed WT mice compared to normal air-exposed WT 376 
controls (Figure 6T). In contrast, TNFα protein levels were not altered in CS-exposed Tlr2-/- 377 
and Tlr4-/- mice when compared to normal air-exposed Tlr2-/- and Tlr4-/- mice, respectively. 378 
The lack of increase in CS-exposed Tlr2-/- mice was due to increases in levels in normal air-379 
exposed Tlr2-/- mice compared normal air-exposed WT mice. Notably, TNFα protein was 380 
significantly reduced in CS-exposed Tlr4-/- mice compared to CS-exposed WT controls. 381 
 382 
CS-induced Collagen Deposition is not Altered in TLR2-deficeint Mice but 383 
Completely Ablated in TLR4-deficient Mice with Experimental COPD 384 
We have previously shown that mice develop small airway remodeling and fibrosis in 385 
experimental COPD (7, 40, 41, 62). In agreement with this, CS exposure of WT mice 386 
increased small airway epithelial cell area (epithelial thickening) compared to normal air-387 
exposed WT controls (Figure 7A). CS-exposed Tlr2-/- and Tlr4-/- mice also had increased 388 
small airway epithelial cell thickening compared to their respective normal air-exposed 389 
controls, but were not altered compared to CS-exposed WT controls. CS-induced small 390 
airway epithelial cell thickening in WT, Tlr2-/- and Tlr4-/- mice was associated with increased 391 
numbers of nuclei in the small airways, which is an indicator of increased numbers of 392 
epithelial cells (Figure 7B). The numbers of nuclei in CS-exposed Tlr2-/- and Tlr4-/- mice 393 
were not altered compared to CS-exposed WT controls. 394 
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We next assessed airway fibrosis in terms of collagen deposition around small 395 
airways. As expected, CS-exposed WT mice had increased collagen deposition compared to 396 
normal air-exposed WT controls (Figure 7C). However, CS-exposed Tlr2-/- and Tlr4-/- mice 397 
did not have increased collagen deposition compared to their respective normal air-exposed 398 
controls. The former was due to an increase in collagen deposition in normal air-exposed 399 
Tlr2-/- mice compared normal air-exposed WT controls. The latter was due to no increase in 400 
collagen deposition in CS-exposed Tlr4-/- mice compared to normal air-exposed Tlr4-/- 401 
controls. Notably, CS-induced collagen deposition was attenuated in CS-exposed Tlr4-/- mice 402 
compared to CS-exposed WT controls. This was associated with a concomitant increase in 403 
the levels of hyaluronan in BALF and fibronectin mRNA expression in lung homogenates in 404 
Tlr4-/- compared to WT mice, independent of CS exposure (Figure 7D-E). Notably, CS-405 
induced expression of IL-33 mRNA was also attenuated in Tlr4-/- mice (Figure 7F). 406 
 407 
CS-induced Emphysema-like Alveolar Enlargement, Apoptosis and Lung 408 
Function Impairment are Increased in TLR2-deficient Mice and Decreased 409 
in TLR4-deficient Mice with Experimental COPD 410 
We have previously shown that CS-exposed WT mice developed emphysema-like alveolar 411 
enlargement and impaired lung function after 8 weeks of CS exposure (7, 40, 41, 62). Thus, 412 
we next sought to determine whether TLR2 and TLR4 contribute to these disease features. In 413 
agreement with our previous studies, CS-exposed WT mice had significantly increased 414 
alveolar septal damage and diameter, determined by destructive index and mean linear 415 
intercept techniques respectively, compared to normal air-exposed WT controls (Figure 8A-416 
B). CS-exposed Tlr2-/- and Tlr4-/- mice also had increased alveolar septal damage and alveolar 417 
diameter compared to normal air-exposed Tlr2-/- and Tlr4-/- controls respectively. However, 418 
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CS-exposed Tlr2-/- mice had increased alveolar damage and diameter compared CS-exposed 419 
WT controls. Conversely, CS-exposed Tlr4-/- mice had reduced alveolar septal damage and 420 
diameter compared CS-exposed WT controls. 421 
We have previously shown that increased CS-induced emphysema-like alveolar 422 
enlargement was associated with increased numbers of TUNEL+ cells in the parenchyma, 423 
which indicates increased apoptosis (41). In agreement with this, CS-exposed WT mice had 424 
increased TUNEL+ cells in the parenchyma compared to normal air-exposed WT controls 425 
(Figure 8C). CS-exposed Tlr2-/- mice had increased TUNEL+ cells in the parenchyma 426 
compared to normal air-exposed Tlr2-/- controls. Importantly, and in agreement with the 427 
reduced emphysema-like alveolar enlargement, CS-exposed Tlr4-/- mice did not have 428 
increased apoptosis compared to normal air-exposed Tlr4-/- controls. Accordingly, the 429 
numbers of TUNEL+ cells were increased in CS-exposed Tlr2-/- mice, but reduced 430 
significantly in CS-exposed Tlr4-/- mice compared to CS-exposed WT controls. 431 
To provide further evidence for changes in apoptosis we also assessed the levels of 432 
active caspase-3, a key molecular marker of apoptosis (19, 34, 79), in whole lung sections by 433 
immunohistochemistry. Caspase-3 levels were increased in the lung parenchyma of CS-434 
exposed WT mice compared to normal air-exposed WT controls (Figure 8D). Caspase-3 was 435 
also increased in the lung parenchyma of CS-exposed Tlr2-/- mice compared to normal air-436 
exposed Tlr2-/- controls. In contrast, caspase-3 levels were not altered in lung parenchyma of 437 
CS-exposed Tlr4-/- mice compared to normal air-exposed Tlr4-/- controls. Notably, the levels 438 
of caspase-3 were increased in CS-exposed Tlr2-/- mice but significantly reduced in CS-439 
exposed Tlr4-/- mice compared to CS-exposed WT mice, whilst they were significantly 440 
reduced in CS-exposed Tlr4-/- mice compared to CS-exposed WT mice. 441 
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We next assessed the roles of TLR2 and TLR4 in CS-induced impairment of lung 442 
function, measured in terms of TLC and transpulmonary resistance. As expected, CS-exposed 443 
WT mice had increased TLC (Figure 8E) and transpulmonary resistance (Figure 8F) 444 
compared with normal air-exposed WT controls. CS-exposed Tlr2-/- mice did not have altered 445 
TLC compared to normal air-exposed Tlr2-/- controls. This was due to increased TLC in 446 
normal air-exposed Tlr2-/- mice compared to normal air-exposed WT controls. However, CS-447 
exposed Tlr2-/- mice did have increased transpulmonary resistance compared to normal air-448 
exposed Tlr2-/- mice. Notably, both TLC and transpulmonary resistance were significantly 449 
increased in CS-exposed Tlr2-/- mice compared to CS-exposed WT mice. In contrast, Tlr4-/- 450 
mice did not have increases in TLC and transpulmonary resistance compared to normal air-451 
exposed Tlr4-/- controls.  452 
 453 
DISCUSSION 454 
In this study, we demonstrate that both TLR2 and TLR4 play important, but opposing 455 
roles, in the pathogenesis of CS-induced experimental COPD. TLR2 and TLR4 mRNA were 456 
increased in airway epithelium and parenchyma of mice chronically exposed to CS and in 457 
human COPD patients. Expression of the co-receptors TLR1, TLR6, CD14 or MD2/Ly96 458 
were also increased in CS-exposed mice and human COPD. CS-induced pulmonary 459 
inflammation was unaltered in Tlr2-/- and Tlr4-/- mice compared to WT controls. In contrast, 460 
Tlr2-/- mice had increased CS-induced emphysema-like alveolar enlargement, apoptosis and 461 
impaired lung function, whilst importantly these features were reduced in Tlr4-/- mice. CS-462 
induced small airway epithelial thickening and fibrosis were not altered in Tlr2-/- mice when 463 
compared to CS-exposed WT controls. In contrast, CS-induced airway fibrosis, but not small 464 
airway epithelial thickening, was significantly attenuated in Tlr4-/- mice compared to CS-465 
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exposed WT controls. This study provides new insights into the role of TLR2 and TLR4 in 466 
the pathogenesis of COPD.  467 
The roles of TLR2 and TLR4 in the pathogenesis of COPD are controversial with 468 
conflicting data in the literature (3, 21, 22, 30, 33, 65, 66, 69, 75, 80, 85, 87, 91). These 469 
conflicting data are likely due to differences between experimental analytes (e.g. peripheral 470 
blood monocytes vs. macrophages), cohorts of patients with varying medical backgrounds, 471 
potential tissue-specificity of TLR expression and the experimental models used (e.g. acute 472 
vs. chronic CS exposure). Notably, the experimental models utilized either in vitro, acute or 473 
whole body CS exposure models, which do not replicate in vivo chronic inhaled mainstream 474 
CS exposure associated with the induction of COPD in humans (3, 21, 66, 75). Furthermore, 475 
these models did not report or demonstrate chronic CS-induced impairment of lung function, 476 
which is a key feature of human COPD (7, 31).  477 
We aimed to address these discrepancies and delineate the roles of TLR2 and TLR4 in 478 
COPD by using an established mouse model of tightly controlled chronic nose-only CS-479 
induced experimental COPD (7, 29, 31, 40, 41, 47, 100). Our models are representative of a 480 
pack-a-day smoker and 8 weeks of smoking in a mouse that lives for a year is equivalent to 481 
10 years in a human smoker (31, 51). Importantly, we have consistently shown that 8 weeks 482 
of CS exposure in our models is sufficient to induce the hallmark features of human COPD: 483 
chronic inflammation, airway remodelling, emphysema and impaired lung function (7, 13, 484 
16, 29, 31, 40, 41, 47, 100, 102). This 8-week timepoint was specifically chosen to 485 
investigate the underlying pathogenic mechanism(s) during the early stages (GOLD I/II) and 486 
identify potential therapeutic targets to halt the progression of COPD. Moreover, these 487 
shorter term models may be relevant for testing of therapeutic interventions because new 488 
therapeutics such as targeting TLR signaling are likely to have little effect during more severe 489 
stages of disease, when invasive interventions, such as lung surgery/transplant, may be 490 
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required (103). Although it is possiblethere is a possibility that nose-only inhalation murine 491 
models of emphysema may introduce other variables such as stress-related to restraint, we 492 
observe that mice quickly acclimatize and grow accustomed to our purpose-built restraining 493 
tubes (7). This is reflectedconfirmed by an initial increase in blood corticosterone levels 494 
(indicator of stress) in restrained mice during the first week of CS exposure, but these levels 495 
returned to baseline after that (unpublished data). 496 
Interestingly, Tlr2-/- mice have not been assessed in the context of CS-induced 497 
pathogenesis of COPD.  whilst Tlr4-/- mice on a variety of backgrounds (e.g. C3H/HeJ, 498 
C57BL/10ScNJ or C57BL/6J) have been investigated in other CS-exposure models (21, 66), 499 
h. However, Tlr4-/- mice on a BALB/c background have not been investigated. Given that 500 
MyD88 is the common downstream signaling molecule of all TLRs including both TLR2 and 501 
TLR4 (1, 52) we also subjected MyD88-/- mice to CS-induced experimental COPD to 502 
determine if TLR2- and TLR4-mediated effects were MyD88-dependent. However, these 503 
mice became very ill and suffered significant weight loss (>15% body weight) after 3-4 504 
weeks of CS exposure (data not shown). MyD88-/- mice are known to be susceptible to 505 
opportunistic infections and this was the likely cause of illness in these mice (9, 98). 506 
Hence, our study adds to the current literature by investigating the pathogenesis of 507 
COPD with, previously uninvestigated, Tlr2-/- and Tlr4-/- on a BALB/c background. 508 
Moreover, our study also used an established experimental COPD model that utilizes a more 509 
clinically relevant CS exposure protocol and is supported by gene expression analysis of 510 
published human microarray datasets from healthy non-smokers and COPD subjects (7, 13, 511 
16, 29, 31, 40, 41, 47, 100, 102).  512 
We showed that TLR2 mRNA was increased in blunt dissected airways and 513 
parenchyma, whereas TLR4 mRNA was increased only in the airways. This suggests that the 514 
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expression of TLR2 and TLR4 may be tissue-specific within the lung, which may in part 515 
explain the discrepancies in the literature on the expression of TLR2 and TLR4 in COPD. 516 
Interestingly, the expression of TLR2 and TLR4 were not altered in lung-isolated 517 
macrophages from CS-exposed mice. This indicates that CS-induced increases in TLR 518 
expression occurs on small airway epithelial cells whilst influxing macrophages may 519 
contribute by having constitutive levels of TLR expression and by increasing in numbers. 520 
These observations were confirmed with immunohistochemistry that showed that TLR2 and 521 
TLR4 expressions were detected on small airway epithelial cells and parenchymal 522 
inflammatory cells, which were significantly increased in experimental COPD. Furthermore, 523 
subsequent flow cytometry analysis showed CS exposure increased the numbers of TLR2- 524 
and/or TLR4-expressing neutrophils and mDCs in the lungs. These results mirrorwere in line 525 
with previous studies, by us and others, that showed TLR2 and/or TLR4 awere expressed on 526 
various cells, including macrophages, peripheral monocytes, neutrophils, mDCs and 527 
airway/bronchial epithelial cells in inflammatory disease setting including experimental and 528 
human COPD (3, 6, 10, 22, 33, 65, 69, 75, 80, 81, 85, 87, 91). 529 
Importantly, using pre-existing microarray datasets, we also showed that the 530 
expression of TLR2 and TLR4 mRNA was increased in airway epithelial cells from bronchial 531 
brushings of patients with mild to moderate COPD. In contrast, TLR2 and TLR4 mRNA 532 
were reduced in lung parenchymal cores from patients with severe COPD. Interestingly, a 533 
previous human study also described similar observations whereby TLR4 expression was 534 
increased in the nasalairway epithelium in mild-to-moderate COPD (FEV1 >1L) but reduced 535 
in severe diseaseCOPD (FEV1 <1L) (65). Collectively, these data suggest that TLR2 and 536 
TLR4 expression is increased in the lung parenchyma early in disease in response to CS-537 
exposure, but are reduced in of severe COPD patients, which may be due to increasedgreater 538 
tissue destruction that results in the loss of tissues/cells expressing these TLRs. This also may 539 
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explain the current discrepancies in the literature on the expression of TLR2 and TLR4 in 540 
COPD. 541 
Others have shown that TLR1 and TLR6 were increased on CD8+ T cells from COPD 542 
patients (30), and that CD14 levels were increased by CS and associated with impaired lung 543 
function in smokers (17, 110). It has been reported that MD2 expression was unaltered in 544 
small airway epithelium, but was reduced in the large airways of smokers and patients with 545 
stable COPD (74). These data suggest that the effects of CS on the expression of TLR2 and 546 
TLR4 co-receptors may also be tissue- or cell-specific (e.g. airway epithelium vs. 547 
inflammatory cells) and dependent on the severity of the disease. Thus, ligation of TLR2 and 548 
TLR4 with their co-receptors may also partially explain the discrepancies in the current 549 
literature. 550 
In contrast to our observations in Tlr2-/- mice, previous studies showed that inhibition 551 
of TLR2 reduced pulmonary inflammation, apoptosis and lung function impairment in other 552 
chronic lung diseases, including pulmonary fibrosis and asthma  (59, 106). Mice deficient in 553 
TLR2 or treated with a neutralizing antibody had reduced bleomycin-induced pulmonary 554 
inflammation, collagen deposition and hydroxyproline levels in the lungs (106). Moreover, 555 
Tlr2-/- mice had reduced airway inflammation and peri-bronchial collagen deposition in an 556 
OVA-induced model of experimental allergic asthma (59). In addition, TLR2 was shown to 557 
promote apoptosis in human kidney epithelial (HEK)-293, human monocytic (THP-1) cells 558 
and endothelial cells in vitro (2, 81). Ovalbumin-induced airway hyperresponsiveness (AHR) 559 
were also previously shown to be reduced in Tlr2-/- mice (38, 59). This may be due to 560 
differences in pathogenesis, mechanisms and inflammatory cells/responses that may dictate 561 
the role of TLR2 in various chronic lung diseases. For example, allergic asthma is dominated 562 
by aberrant Th2-type responses typified by increased infiltration of eosinophils and activated 563 
mast cells into the airways and increased levels of Th2-associated cytokines such as IL-5 and 564 
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IL-13 (44, 45, 95, 96).  In contrast, COPD is typically associated with Th1/Th17-type 565 
inflammatory responses characterized by infiltration of macrophages, neutrophils and 566 
cytotoxic T cells and the production of Th1/Th17-associated cytokines such as IFN-γ and IL-567 
17A (7, 30, 69, 80, 91). Hence, the role of TLR2 in different chronic lung diseases may 568 
largely depend on the presence and type of specific TLR2-expressing cells. Nevertheless, our 569 
studies suggest that TLR2 may potentially have a protective role in CS-induced COPD. The 570 
underlying mechanism remained unclear, but appeared to be independent of oxidative stress 571 
in the lung.  572 
Interestingly, inflammatory infiltrates in the airway lumen and around blood vessels, 573 
TNFα protein and TLC were increased in normal air-exposed Tlr2-/- mice compared WT 574 
controls. Previous studies showed that airway inflammation is negatively associated with 575 
lung function (4, 8) and may cause lung hyperinflation (increased in TLC) (28, 49, 76). 576 
Moreover, increased sputum inflammatory cells (e.g. neutrophils) have been shown to 577 
significantly correlate with air trapping in COPD patients (71, 72). Another study showed 578 
that TLR2 was highly expressed in human fetal lungs and may be important in regulating the 579 
development of this organ (77). Recent studies also have emerged that highlight the 580 
importance and interactions of host microbiome, commensal bacteria, infectious 581 
exacerbations and TLRs in shaping and regulating immune responses in COPD and other 582 
chronic respiratory diseases (11, 14, 15, 43, 68, 89). Taken together, the increased 583 
inflammation and TLC observed in normal air-exposed Tlr2-/- mice may be a consequence of 584 
altered host immune responses, lung development and/or microbiome composition. It is 585 
likely that TLR2 and TLR4 will be important in these interactions and during lung 586 
development. However, this is outside the scope of this study and will require further work to 587 
delineate the relationships. 588 
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TLR4 has been implicated in CS-induced pulmonary inflammation (21, 66). In other 589 
studies, acute (3 days) CS exposure of Tlr4-/- mice on a C57BL/6 background resulted in 590 
reductions in total inflammatory cells in BALF and lung tissue (21). Sub-acute (5 weeks) 591 
exposure of Tlr4defective mice also resulted in reduced numbers of BALF total inflammatory 592 
cells compared to WT C3H/HeJ controls (66). However, in support of our observations, the 593 
numbers of BALF total inflammatory cells were not significantly different in these 594 
Tlr4defective mice compared to WT C3H/HeJ controls following chronic CS exposure (26 595 
weeks) (66). Collectively, these suggest TLR4 may play only a minor role at the chronic and 596 
severe stages of the disease. Whilst CS-exposed Tlr4-/- mice had increased pro-inflammatory 597 
cytokine TNFα mRNA expression in the lung compared to CS-exposed WT controls, this 598 
increase in mRNA expression was in contrast to the significant reduction in TNFα protein 599 
levels in CS-exposed Tlr4-/- mice. Taken together, these results suggest that there are 600 
alterations in the regulation of gene transcriptional regulation and post-translational protein 601 
modificationsproduction in CS-exposed Tlr4-/- mice, which collectively does not affect 602 
airway or parenchymal inflammation. The biology of these changes is not understood.  603 
We previously showed that parenchymal inflammatory cells and alveolar destruction 604 
were further increased in WT mice after 12 weeks of CS compared to those exposed to CS 605 
for 8 weeks (7). Hence, increasing CS exposure time in mice (e.g. from 8 to 12 weeks) may 606 
lead to further alterations in inflammatory gene expression and inflammation. However, 607 
given that TLR2 and TLR4 expression were reduced in lung parenchymal cores from severe 608 
(GOLD III/IV) COPD patients (Figure 2), we speculate that increasing CS exposure time to 609 
induce more severe disease in our model may have similar effects and promote further loss of 610 
tissue/cells expressing TLR2 and/or TLR4. In support of this, a previous human study also 611 
found that TLR4 expression was inversely proportional to COPD severity (65). Moreover, we 612 
also showed that the expression of pro-inflammatory TNF-α and chemokine CXCL1 were not 613 
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increased further with longer exposures, despite an increasesd in parenchymal inflammatory 614 
cells, in WT mice exposed to CS for 12 weeks of CS compared to those exposed for 8 weeks 615 
(7). This may be due to some of the functional/molecular changes being restricted to specific 616 
cell types (e.g. structural versus immune cells) that expressed TLR2 and/or TLR4 in the lung. 617 
Hence, profiling functional/molecular changes in whole lung tissue may have concealed 618 
small but potentially critical functional/molecular changes. TIn addition, the roles of TLRs 619 
(TLR2 or TLR4) on specific cells in the lungs also remains unclear. This could be addressed 620 
in future studies using cell-specific TLR-/- mice or bone marrow chimera studies using Tlr2-/- 621 
or Tlr4-/- mice to delineate the role of TLRs on inflammatory versus structural cells. 622 
 CS-induced small airway fibrosis was significantly reduced in lungs of Tlr4-/- mice 623 
compared to WT controls. Others have proposed that hyaluronan plays a role in modulating 624 
the expression of fibronectin and pulmonary fibrosis in a TLR4-dependent manner (50, 107). 625 
Moreover, IL-33 is known to be a pro-fibrotic factor and has been shown to be important in 626 
chronic lung diseases, including COPD and asthma (20, 84, 105). Thus, the reduction in 627 
small airway fibrosis in Tlr4-/- mice may result from the impairment of the effects of 628 
hyaluronan in BALF and IL-33 and fibronectin in the lungs. TLR4 also plays a critical role in 629 
bleomycin-induced pulmonary fibrosis (42, 58, 60, 86). TLR4 mRNA expression was 630 
increased in mice administered with bleomycin (58), and Tlr4-/- mice were protected against 631 
bleomycin-induced pulmonary fibrosis (increased lung collagen levels) and mortality (60). 632 
Inhibition of TLR4 with an antagonist (E5564) or an inhibitory small hairpin RNA also 633 
reduced collagen synthesis and secretion in the lungs (42, 86). Our data further these 634 
observations by showing that TLR4 is a mediator of small airway fibrosis induced by CS. 635 
Previous studies suggest that mice deficient in, or with mutations of, TLR4 on other 636 
genetic backgrounds (e.g. C3H/HeJ and C57BL/10ScNJ) developed spontaneous emphysema 637 
after 3 months of age in the absence of noxious challenges such as CS (104, 109). This was 638 
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associated with increased Nox3 expression in lungs of these mice (104, 109). We also 639 
observed an increase in Nox3 mRNA in normal air-exposed Tlr4-/- BALB/c mice, however, 640 
these mice did not develop spontaneous emphysema even at 15-16 weeks of age. In fact, 641 
Tlr4-/- mice were protected from CS-induced emphysema-like alveolar enlargement, which 642 
was associated with reduced apoptosis in the lungs. These findings were supported by the 643 
observation of reduced expression of MMP-12, which has been linked to the induction of 644 
emphysema (7, 41), and improved lung function in CS-exposed Tlr4-/- mice. Moreover, CS 645 
exposure appeared to reduce Nox3 mRNA expression in Tlr4-/- BALB/c mice back to levels 646 
observed in WT BALB/c mice. 647 
The differences in genetic background may account for the conflicting results. For 648 
example, spontaneous chronic lung disease (severe lung inflammation, increased collagen 649 
deposition and alveolar wall thickening) only manifest in Src homology 2 domain–containing 650 
inositol-5-phosphatase 1 (SHIP-1)-deficient C57BL/6, but not BALB/c mice (23, 67). In the 651 
context of human COPD, this may be important as the severity of the disease in humans often 652 
varies between individuals and genetic make-up in combination with environmental 653 
exposures are critical. These observations highlight the potential importance of genetic 654 
factors in predisposing certain individuals to COPD. This is clinically relevant as only 50% 655 
of life-long smokers developed COPD (64). Importantly, this may also indicate that certain 656 
individuals may respond better to TLR-based interventions such as Eritoran (currently in 657 
phase 3 clinical trial (73)). Eritoran is a synthetic TLR4 antagonist and was shown to protect 658 
mice against acute lethal influenza infection (88). 659 
Our study demonstrates a previously unrecognized protective role for TLR2 in the 660 
pathogenesis of COPD. This supports current evidence in the literature that shows a loss-of-661 
function polymorphism in the TLR2, but not TLR4, gene is associated with accelerated lung 662 
function declines in COPD patients (12). TLR2 polymorphisms also predispose patients with 663 
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other chronic lung diseases (e.g. cystic fibrosis) to rapid lung function decline (35). This 664 
further highlights the potential protective role of TLR2 in chronic lung diseases, and 665 
screening for TLR2 polymorphisms may be useful in the prognosis of COPD patients. 666 
Furthermore, using a clinically-relevant and established model of CS-induced COPD, our 667 
study demonstrates that TLR4 promotes CS-induced airway fibrosis, apoptosis, emphysema-668 
like alveolar enlargement and lung function impairment. Hence, activating TLR2 and/or 669 
inhibiting TLR4 may be potential therapeutic strategies in COPD. 670 
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FIGURE LEGENDS 1092 
Figure 1. TLR2 and TLR4 mRNA expression and protein levels are increased in CS-1093 
induced experimental COPD. Wild-type (WT) BALB/c mice were exposed to normal air or 1094 
CS and sacrificed after 4, 8 and 12 weeks. (A) TLR2 and (B) TLR4 mRNA expression in 1095 
whole lung tissues. (C) Muc5ac and Sftpc mRNA expressions in blunt dissected airways and 1096 
parenchyma from in normal air-exposed mice. (D-E) TLR2 and (F-G) TLR4 mRNA 1097 
expression in blunt dissected airways and parenchyma after 8 weeks CS exposure. 1098 
Immunohistochemistry for (H-I) TLR2 and (J-K) TLR4 protein on small airway epithelium 1099 
and lung parenchyma after 8 weeks of CS exposure; scale bars equal 50µm. Arrowheads 1100 
indicate TLR2 or TLR4 expressing inflammatory cells. TLR2 and TLR4 mRNA expression 1101 
were normalized to reference gene and expressed as relative abundance compared to normal 1102 
air-exposed controls. Graphs were presented as mean ± SEM and representative from two 1103 
independent experiments of 6 mice per group. Two-tailed Mann-Whitney t-test analyzed 1104 
differences between two groups, whereby *p<0.05; **p<0.01; ***p<0.001 compared to 1105 
normal air-exposed controls and #p<0.05; ###p<0.001 compared to bluntly dissected airway.  1106 
 1107 
Figure 2. TLR2- and/or TLR4-expressing neutrophils and mDCs cells were increased in 1108 
CS-induced experimental COPD. Wild-type (WT) BALB/c mice were exposed to cigarette 1109 
smoke (CS) or normal air for 8 weeks. (A) TLR2 and (B) TLR4 mRNA expressions was 1110 
determined in macrophage isolated from lungs by qPCR. The number of (C) CD11b+ 1111 
monocytes, (D) neutrophils and (E) myeloid dendritic cells (mDCs) expressing TLR2 and/or 1112 
TLR4 in lungs. mRNA expressions were normalized to reference gene and expressed as 1113 
relative abundance compared to normal air-exposed WT controls. Graphs were presented as 1114 
mean ± SEM and representative from two independent experiments of 6 mice per group. 1115 
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Two-tailed Mann-Whitney t-test analyzed differences between two groups in Figure A and B. 1116 
The one-way analysis of variance with Bonferroni post-test analyzed differences between 3 1117 
or more groups for Figure C, D and E, whereby *p<0.05; **p<0.01 compared to normal air-1118 
exposed WT. 1119 
 1120 
Figure 3. TLR2 and TLR4 co-receptor expression are increased in CS-induced 1121 
experimental COPD. Wild-type (WT) BALB/c mice were exposed to normal air or CS for 8 1122 
weeks to induce experimental COPD. (A-B) TLR1, (C-D) TLR6, (E-F) CD14 and (G-H) 1123 
MD2/Ly96 mRNA expressions in blunt dissected airways and parenchyma. mRNA 1124 
expressions were normalized to reference gene and expressed as relative abundance 1125 
compared to normal air-exposed controls. Graphs were presented as mean ± SEM and 1126 
representative from two independent experiments of 6 mice per group. Two-tailed Mann-1127 
Whitney t-test analyzed differences between two groups, whereby *p<0.05; **p<0.01; 1128 
***p<0.001 compared to normal air-exposed controls.  1129 
 1130 
Figure 4. TLR2, TLR4 and co-receptor mRNA expressions are increased in the airways 1131 
in humans with mild to moderate COPD. Airway epithelial cells were collected from 1132 
human healthy non-smokers (NS), healthy smokers without COPD (Smoker) and COPD 1133 
patients with Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage I (Mild) 1134 
or II (Moderate) disease. (A) TLR2, (B) TLR4, (C) TLR1, (D) TLR6, (E) CD14 and (F) 1135 
LY96 mRNA expression were assessed by microarray profiling. Lung parenchymal cores 1136 
were collected from human healthy non-smokers (NS) and COPD patients with Global 1137 
Initiative for Chronic Obstructive Lung Disease (GOLD) stage IV (severe) disease. (G) 1138 
TLR2, (H) TLR4, (I) TLR1, (J) TLR6 and (K) LY96 mRNA expression were assessed by 1139 
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microarray profiling. Graphs are expressed as log2 intensity robust multi-array average 1140 
signals. The Benjamini–Hochberg method for adjusted P value/false discovery rate (FDR) 1141 
analyzed differences between NS or Smoker and COPD patients.  1142 
 1143 
Figure 5. CS-induced pulmonary inflammation is unaltered in TLR2-deficient and 1144 
TLR4-deficient mice with experimental COPD. Wild-type (WT), TLR2-deficient (Tlr2-/-) 1145 
or TLR4-deficient (Tlr4-/-) BALB/c mice were exposed to normal air or CS for 8 weeks to 1146 
induce experimental COPD. (A) Total leukocytes, (B) macrophages, (C) neutrophils and (D) 1147 
lymphocytes were enumerated in May-Grunwald Giemsa stained bronchoalveolar lavage 1148 
fluid (BALF) cytospin slides. (E) The numbers of parenchymal inflammatory cells 1149 
(arrowheads) were enumerated in periodic acid-Schiff (PAS)-stained lung sections; scale bars 1150 
equal 20µm. (G-I) Histopathology score in lung sections; specifically, in the airway, vascular 1151 
and parenchymal regions. (J) Representative images of lung histopathology scoring; scale 1152 
bars equal 50µm. Graphs were presented as mean ± SEM and representative from two 1153 
independent experiments of 6 mice per group. The one-way analysis of variance with 1154 
Bonferroni post-test analyzed differences between 3 or more groups, whereby *p<0.05; 1155 
**p<0.01; ***p<0.001; ****p<0.0001 compared to normal air-exposed WT, Tlr2-/- or Tlr4-/- 1156 
controls, #p<0.05; ##p<0.01 compared to CS-exposed WT controls and ϕp<0.05; ϕϕp<0.01; 1157 
ϕϕϕp<0.001 compared to normal air-exposed WT controls.  1158 
 1159 
Figure 6. Pro-inflammatory cytokine, chemokine, COPD-related factors and oxidative 1160 
stress-associated gene expressions in CS-induced experimental COPD. Wild-type (WT), 1161 
TLR2-deficient (Tlr2-/-) or TLR4-deficient (Tlr4-/-) BALB/c mice were exposed to normal air 1162 
or cigarette smoke (CS) for 8 weeks. Pro-inflammatory cytokine (A) tumor necrosis factor 1163 
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(TNF)-α, (B) chemokine (C-X-C motif) ligand (CXCL)1, (C) chemokine (C-C motif) ligand 1164 
(CCL)2, (D) CCL3, (E) CCL4, (F) CCL12, (G) CCL22, other COPD-related factors; (H) 1165 
matrix metalloproteinase (MMP)-12 and (I) serum amyloid A3 (SAA3) mRNA expression 1166 
was determined in whole lung homogenates by qPCR. Oxidative stress-associated genes (J) 1167 
NADPH oxidase (Nox)1, (K) Nox2, (L) Nox3, (M) Nox4, (N) NAD(P)H quinone 1168 
dehydrogenase (Nqo)1, (O) nuclear factor, erythroid 2 like 2 (Nrf2), (P) glutamate-cysteine 1169 
ligase catalytic subunit (Gclc), (Q) glutathione peroxidase (Gpx)2, (R) heme oxygenase 1170 
(Hmox)1 and (S) glutathione S-transferase pi (Gstp)1 expression was determined in whole 1171 
lung homogenates by qPCR. mRNA expression was normalized to the reference gene HPRT 1172 
and expressed as relative abundance compared to normal air-exposed WT controls. (T) The 1173 
levels of TNFα protein in lung homogenates were determined by ELISA and normalized to 1174 
total protein. Graphs were presented as mean ± SEM and representative from two 1175 
independent experiments of 6 mice per group. The one-way analysis of variance with 1176 
Bonferroni post-test was used to analyze differences between 3 or more groups, whereby 1177 
*p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 compared to normal air-exposed WT, Tlr2-/- 1178 
or Tlr4-/- controls, #p<0.05; ##p<0.01; ###p<0.001; ####p<0.0001 compared to CS-exposed 1179 
WT controls, ϕp<0.05; ϕϕϕϕp<0.0001 compared WT air controls and ns denotes not 1180 
significant. 1181 
 1182 
Figure 7. CS-induced airway remodeling and fibrosis is not altered in TLR2-deficient 1183 
mice whilst CS-induced airway fibrosis, but not remodeling, is completely ablated in 1184 
TLR4-deficient mice with experimental COPD. Wild-type (WT), TLR2-deficient (Tlr2-/-) 1185 
or TLR4-deficient (Tlr4-/-) BALB/c mice were exposed to normal air or CS for 8 weeks to 1186 
induce experimental COPD. (A) Small airway epithelial thickness in terms of epithelial cell 1187 
area (μm2) per basement membrane (BM) perimeter (μm) was determined in periodic acid-1188 
 Opposing roles of TLR2 and TLR4 in pathogenesis of COPD  
  44
Schiff (PAS)-stained whole lung sections; scale bars equal 50µm. (B) The number of 1189 
epithelial cells in PAS-stained lung sections was assessed by enumerating the number of 1190 
nuclei per 100μm of BM perimeter; scale bars equal 20µm. (C) Area of collagen deposition 1191 
(μm2) per BM perimeter (μm) was determined in Masson’s Trichrome-stained lung sections; 1192 
scale bars equal 200µm. Inserts show expanded images of indicated regions; scale bars equal 1193 
200μm). (D) The level of hyaluronan in BALF was determined by ELISA. The mRNA 1194 
expression of (E) fibronectin and (F) interleukin (IL)-33 were determined in whole lung 1195 
homogenates by qPCR. mRNA expression was normalized to the reference gene HPRT and 1196 
expressed as relative abundance compared to normal air-exposed WT controls. Graphs were 1197 
presented as mean ± SEM and representative from two independent experiments of 6 mice 1198 
per group. The one-way analysis of variance with Bonferroni post-test analyzed differences 1199 
between 3 or more groups, whereby *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 1200 
compared to normal air-exposed WT, Tlr2-/- or Tlr4-/- controls, #p<0.05; ## p<0.01; 1201 
####p<0.0001 compared to CS-exposed WT controls, ϕp<0.05; ϕϕϕϕp<0.0001 compared to 1202 
normal air-exposed WT controls and ns denotes not significant. 1203 
 1204 
Figure 8. CS-induced emphysema-like alveolar enlargement, apoptosis and impaired 1205 
lung function are increased in TLR2-deficient mice and decreased in TLR4-deficient 1206 
mice with experimental COPD. Wild-type (WT), TLR2-deficient (Tlr2-/-) or TLR4-1207 
deficient (Tlr4-/-) BALB/c mice were exposed to normal air or CS for 8 weeks to induce 1208 
experimental COPD. (A) Alveolar septal damage and (B) diameter (μm) were determined in 1209 
H&E-stained lung sections using destructive index and mean linear intercept techniques 1210 
respectively; scale bars equal 50µm. (C) The numbers of TUNEL+ cells (arrowheads) were 1211 
enumerated in whole lung sections at high power field (HPF; 100x); scale bars equal 20µm. 1212 
Immunohistochemistry for (D) active cCaspase- 3 protein on lung parenchyma after 8 weeks 1213 
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of CS exposure; scale bars equal 50µm. Arrowheads indicate cCaspase- 3-expressing alveolar 1214 
septa cells. Lung function was assessed in terms of (E) total lung capacity (TLC) and (F) 1215 
transpulmonary resistance. Graphs were presented as mean ± SEM and representative from 1216 
two independent experiments of 6 mice per group. The one-way analysis of variance with 1217 
Bonferroni post-test analyzed differences between 3 or more groups, whereby **p<0.01; 1218 
***p<0.001; ****p<0.0001 compared to normal air-exposed WT, Tlr2-/- or Tlr4-/- controls, 1219 
#p<0.05; ##p<0.01; ####p<0.0001 compared to CS-exposed WT controls, ϕϕϕϕp<0.0001 1220 
compared to normal air-exposed WT controls and ns denotes not significant.  1221 
1222 
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Table 1. Custom-designed primers used in qPCR analysis 1223 
Primer Primer sequence (5’ → 3’) 
TLR2 forward TGTAGGGGCTTCACTTCTCTGCTT 
TLR2 reverse AGACTCCTGAGCAGAACAGCGTTT 
TLR4 forward TGGTTGCAGAAAATGCCAGG 
TLR4 reverse GGAACTACCTCTATGCAGGGAT 
TNF-α forward TCTGTCTACTGAACTTCGGGGTGA 
Muc5ac forward GCAGTTGTGTCACCATCATCTGTG 
Muc5ac reverse GGGGCAGTCTTGACTAACCCTCTT 
Sftpc forward TGTATGACTACCAGCGGCTC 
Sftpc reverse AGCGAAAGCCTCAAGACTAGG 
TNF-α reverse TTGTCTTTGAGATCCATGCCGTT 
CXCL1 forward GCTGGGATTCACCTCAAGAA 
CXCL1 reverse CTTGGGGACACCTTTTAGCA 
CCL2 forward TGAGTAGCAGCAGGTGAGTGGGG 
CCL2 reverse TGTTCACAGTTGCCGGCTGGAG 
CCL3 forward CTCCCAGCCAGGTGTCATTTT 
CCL3 reverse CTTGGACCCAGGTCTCTTTGG 
CCL4 forward GTGGCTGCCTTCTGTGCTCCA 
CCL4 reverse AGCTGCCGGGAGGTGTAAGAGAA 
CCL12 forward CCGGGAGCTGTGATCTTCA 
CCL12 reverse AACCCACTTCTCGGGGT 
CCL22 forward TGGCTACCCTGCGTCGTGTCCCA 
CCL22 reverse CGTGATGGCAGAGGGTGACGG 
MMP-12 forward CCTCGATGTGGAGTGCCCGA 
MMP-12 reverse CCTCACGCTTCATGTCCGGAG 
SAA3 forward TGATCCTGGGAGTTGACAGCCAA 
SAA3 reverse ACCCCTCCGGGCAGCATCATA 
Nox1 forward CCCCTGAGTCTTGGAAGTGG 
Nox1 reverse GGGTGCATGACAACCTTGGTA 
Nox2 forward AACTGGGCTGTGAATGAAGG 
Nox2 reverse CAGCAGGATCAGCATACAGTTG 
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Nox3 forward CTCGTTGCCTACGGGATAGC 
Nox3 reverse CCTTCAGCATCCTTGGCCT  
Nox4 forward ACAACCAAGGGCCAGAATACTACTAC 
Nox4 reverse GGATGAGGCTGCAGTTGAGG 
Nqo1 forward GTAGCGGCTCCATGTACTCTC 
Nqo1 reverse AGGATGCCACTCTGAATCGG 
Nrf2 forward CTTTAGTCAGCGACAGAAGGAC 
Nrf2 reverse AGGCATCTTGTTTGGGAATGTG 
Gclc foward CGACCAATGGAGGTGCAGTTA 
Gclc reverse AACCTTGGACAGCGGAATGA 
Gpx2 forward ACCAGTTCGGACATCAGGAG 
Gpx2 reverse CCCAGGTCGGACATACTTGA 
Hmox1 forward GGTGCAAGATACTGCCCCTG 
Hmox1 reverse TGAGGACCCACTGGAGGAG 
Gstp1 forward GGCATGCCACCATACACCAT 
Gstp1 reverse ATTCGCATGGCCTCACACC 
Fibronectin forward TGTGGTTGCCTTGCACGAT 
Fibronectin reverse GCTATCCACTGGGCAGTAAAGC 
IL-33 forward CCTCCCTGAGTACATACAATGACC 
IL-33 reverse GTAGTAGCACCTGGTCTTGCTCTT 
HPRT forward AGGCCAGACTTTGTTGGATTTGAA 
HPRT reverse CAACTTGCGCTCATCTTAGGATTT 
 1224 
1225 
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Table 2. Surface antigens used to characterize mouse lung cell subsets by flow cytometry 1226 
Cell subset Cell surface antigens 
CD11b+ monocyte CD45+ F4/80+ CD11c− CD11b+ Ly6C+TLR2+/− TLR4+/− 
Neutrophil CD45+ F4/80− CD11b+Ly6G+TLR2+/− TLR4+/− 
Myeloid dendritic cell CD45+ F4/80− CD11c+ CD11b+ MHCII+TLR2+/− TLR4+/− 
 1227 
1228 
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Table 3. Antibodies used in flow cytometry analysis 1229 
Cell surface antigens Clone Fluorophore Company 
CD45 30-F11 AF-700 Biolegend 
F4/80 T45-2342 BV711 BD Biosciences 
CD11c HL3 BV421 BD Biosciences 
CD11b M1/70 PerCPCy5.5 Biolegend 
Ly6G 1A8 BV510 Biolegend 
MHCII M5/114.15.2 APC Biolegend 
TLR2 T2.5 FITC Biolegend 
TLR4 MTS510 PE BD Biosciences 
 1230 
